About 1 700 reports

  • BY SEQUENCING SERVICES - GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET SHARE (PERCENT), 2014 - 2018
  • 9.1 GLOBAL NEXT GENERATION SEQUENCING (NGS) - CLINICAL APPLICATIONS

Other Consumables Targeted Re-sequencing (TPS/ WES) RNA Sequencing Whole Genome Sequencing Chip Sequencing De Novo Sequencing Methyl Sequencing ##.

  • Medical Biotechnology
  • World
  • Forecast
  • Illumina, Inc.
  • Oxford Nanopore Technologies Limited
  • 15. DNA NEXT GENERATION SEQUENCING MARKET, KEY COMPANY PROFILES
  • 4.4 KEY MARKET CHALLENGE

FIGURE ##.

  • Medical Biotechnology
  • World
  • Forecast
  • Market Size
  • Agilent Technologies, Inc.
  • 12.5.6 KEY DEVELOPMENTS
  • 3.2 Market Segmentation

LIST OF FIGURES Figure ##.

  • Medical Biotechnology
  • APAC
  • World
  • Forecast
  • Market Size
  • NEXT GENERATION SEQUENCING MARKET
  • 12.5.6 Key Developments

The company also provides services such as, whole-genome sequencing, genotyping, NIPT to conduct whole-genome sequencing projects and microarray projects.

  • Medical Biotechnology
  • Europe
  • World
  • Forecast
  • Market Size
  • GLOBAL NEXT GENERATION MARKET, BY TECHNOLOGY, MARKET SHARE (%), 2016
  • RECENT PARTNERSHIPS IN THE NGS MARKET, 2016-2018

Advancement in genome sequencing has made the sequencing easy and accurate.

  • Medical Biotechnology
  • World
  • Forecast
  • Market Size
  • Illumina, Inc.
  • Description
  • EXPANSIONS

This segment includes flow cytometry, genotyping, single-cell genome sequencing, RNAi gene slicing, and bDNA assays.

  • Medical Biotechnology
  • North America
  • United States
  • Market Size
  • Brazilian Agricultural Research Corporation

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Biotechnology
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Biotechnology
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Biotechnology
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Biotechnology
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Biotechnology
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Biotechnology
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Biotechnology
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Biotechnology
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Biotechnology
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Biotechnology
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics

For data reliability and accurate projections at segment level a ## step methodology has been applied: Step ##: Identification of the total number of labs Step ##: Identification of the total number of laboratories using NA technologies (in several lab units per hospital) Step ##: Interview

  • Biotech Diagnostics
  • Diagnostics
  • Medical Biotechnology
  • Molecular Diagnostics
  • MARKET OVERVIEW

(UK) COMPANY ## COMPANY ## Trovagene, Inc.

  • Medical Biotechnology
  • United States
  • Market Size
  • Biocept, Inc.
  • Biodesix Inc.

Clinical Oncology Next Generation Sequencing (NGS) Market Size & Forecast By Technology (Whole Genome Sequencing, Whole Exon Sequencing, Targeted Sequencing & Resequencing), By Workflow, By End Use And Trend Analysis From 2013 To 2024 Table of Content Chapter ## Research Met

  • Diagnostics
  • Molecular Diagnostics
  • United States
  • Demand
  • Forecast
  • 16.1 ILLUMINA, INC. 16.1.1 Key Facts
  • 15.7.1 The NGS-based RNA-seq Market By Other Growth Strategies

TABLE ##. ##.

  • Medical Biotechnology
  • World
  • Forecast
  • Market Size
  • Illumina, Inc.
  • 16.6.4 Product Portfolio
  • 16.6.3 Financial Overview

TABLE ##.

  • Medical Biotechnology
  • World
  • Forecast
  • Market Size
  • Agilent Technologies, Inc.

## List of Secondary Sources TABLE ## Country share estimation TABLE ## Healthcare expenditure, 2015 TABLE ## NGS top platforms TABLE ## Base pairs sequenced using WGS, WES, and targeted sequencing & resequencing TABLE ## Clonal amplification products in the market TABLE ## North America next g

  • Diagnostics
  • Molecular Diagnostics
  • United States
  • Forecast
  • 12.11 ILLUMINA, INC. 12.11.1 KEY FACTS

The company also offers services that include whole-genome sequencing, genotyping, NIPT to conduct whole-genome sequencing projects and microarray projects.

  • Medical Biotechnology
  • World
  • Forecast
  • Market Size
  • PerkinElmer, Inc.

Cancer is one of the major cause of death.

  • Medical Biotechnology
  • World
  • Forecast
  • Market Size
  • Agilent Technologies, Inc.

Whole Tumor Genome Sequencing ##. ##. ##.

  • Biotechnology
  • Medical Biotechnology
  • Molecular Diagnostics
  • World
  • Forecast

The use of NGS in clinical diagnostic is one of the major factors for future growth of NGS.

  • Diagnostics
  • Genome Sequencing
  • Molecular Diagnostics
  • World
  • Forecast